López ME

Language: Spanish
References: 17
Page: 346-348
PDF size: 0. Kb.

Text Extraction

No abstract

REFERENCES

1. D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.

2. De Franchis R. Evolving consensus in portal hypertension report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-76.

3. D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475-505.

4. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamics events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401-7.

5. Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: and old test as a new prognostic marker in cirrhosis? Hepatology 1997; 25: 245-8.

6. Feu F, García Pagán JV, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.

7. Abraldes J, Tarantino I, Turnes J, García Pagán J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.

8. Bureau C, Peron JM, Alric L. “A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002; 36: 1361-6.

9. Lo GH, Lai KH, Cheng GS. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000; 32: 461-5.

10. De la Peña J, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572-8.

11. Escorcell A, Banares R, Garcia Pagán JC. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trail. Hepatology 2002; 35: 385-92.

12. Bureau C, García Pagán JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469-75.

13. Grace ND, Conn HO, Resnick RH, et al. Distal esplenorenal vs. porto systemic shunts after hemorrage from varices. A randomized control trial. Hepatology 1998; 1475-81.

14. Rosemurgy AS, Goode SE, Zweibel BR, et al. A prospective trial of transjugular intrahepatic portosystemic stent shunt versus small diameter prosthetic H-graft porta-caval shunts in the treatment of bleeding varices. Ann Surg 1996; 224: 378-86.

15. Zacks SL, Sandler RS, Biddle AK, et al. Decision-analysis of transjugular intrahepatic portosystemic shunt versus distal esplenorenal shunt for portal hypertension. Hepatology 1999; 29: 1399-405.

16. Helton WS, Mavez R, Wicks K, et al. Transjugular intrahepatic portosystemic shunt vs surgical shunt in good-risk cirrhotic patients: a case-control comparison. Arch Surg 2001; 136: 17-20.

17. Henderson JM, Boyer T, Kutner M, et al. Distal esplenorenal shunt versus transjugular intrahepatic portosystemic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130: 1643-51.